141080 — LigaChem Biosciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapMomentum Trap

Annual income statement for LigaChem Biosciences, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	49,394	32,157	33,412	34,146	125,898
Cost of Revenue
Gross Profit	35,565	17,698	17,849	17,797	109,948
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	78,888	58,954	84,027	115,298	146,847
Operating Profit	-29,495	-26,797	-50,615	-81,153	-20,948
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-8,827	-20,523	-47,723	-75,747	9,125
Provision for Income Taxes
Net Income After Taxes	-6,986	-23,391	-45,092	-73,704	7,800
Minority Interest
Net Income Before Extraordinary Items
Net Income	-6,986	-23,391	-45,092	-73,704	7,800
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-6,986	-23,391	-45,092	-73,704	7,800
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-315	-989	-1,844	-2,588	227
Dividends per Share